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Patients who have recovered from a prior stroke may experience a reemergence of 
their original stroke syndrome secondary to metabolic derangements, sedation, infec-
tion, and/or fatigue. Critically, the molecular/cellular mechanisms mediating symptom 
recurrence after exposure to analgesic agents remain unknown. Accordingly, herein, we 
report a unique case of a patient with hydromorphone-induced recrudescence 30 years 
after her initial stroke event(s) and in so doing propose a putative mechanism related to 
post-infarction functional neuroplasticity.
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INtRoDUCtIoN
A 44-year-old right-handed woman of Jamaican descent with homozygous sickle-cell anemia compli-
cated by multiple right hemispheric strokes (occurring between the years 1983 and 1986) presented 
with 1 week of 9/10 refractory pain. She was diagnosed with a vaso-occlusive pain crisis and admitted 
to the telemetry floor for pain management and hydration. Her treatment regimen included a basal 
hourly rate of 0.5 mg intravenous (IV) hydromorphone (Dilaudid®) and patient-controlled analgesia 
(PCA) at 0.5 mg IV per 15 min. Within hours of admission, she was found unresponsiveness and 
bradypnic. Rapid response was initiated, and hydromorphone was immediately discontinued. Blood 
pressure and pulse remained stable near baseline 130 s/70 s mmHg and 70 s, respectively. Two doses 
of naloxone (Narcan®), an opioid receptor antagonist, were administered, with gradual improvement 
of her mental status and respiratory rate. STAT non-contrast head computed tomography (CT) was 
negative for acute intracranial pathology (Figure 1A). No additional interventions were made, and 
she was subsequently transferred to the intensive care unit (ICU) for overnight monitoring, where 
she remained hemodynamically and clinically stable. By morning, her somnolence had resolved 
and respiratory rate was stable at 16–17 breaths per minute; however, she endorsed the inability to 
move the left side of her body. Although fully alert and oriented, she was highly inattentive and per-
severative. Cranial nerve examination was notable for sluggishly reactive pupils, left homonymous 
hemianopsia, and a dense left upper motor neuron (LUMN) facial droop. Motor exam (summarized 
in Table 1) demonstrated increased tone and spasticity on the left, with minimal voluntary move-
ment in the left upper and lower extremities. Moreover, she displayed ipsilateral extinction to double 
simultaneous stimulation (DSS) and decreased sensation to light touch and pinprick on the left 
side of the body. Reflexes were brisk in the left upper and lower extremities, with a corresponding 
Babinski reflex. STAT labs were unremarkable for acute toxic-metabolic derangements. Moreover, 
there were no witnessed seizure-like events and/or related symptomatology to suggest a postictal 
taBLe 1 | Focused cranial nerve and motor examination as a function of time after discontinuation of hydromorphone demonstrates transient 
worsening of the neurological exam with progressive return to baseline at 30 h.
examination time after hydromorphone intoxication
Baseline 0 h 10 h 30 h
Pupils 3 → 2 mm briskly reactive 
bilaterally
3 → 2 mm sluggishly reactive 
bilaterally
3 → 2 mm sluggishly reactive 
bilaterally
3 → 2 mm briskly reactive 
bilaterally
Face Symmetric Severe left UMN facial droop Mild left UMN facial droop Symmetric
extremities Right Left Right Left Right Left Right Left
Deltoids (C5) 5 2+ 5 1 5 1 5 2+
Biceps (C6) 5 2+ 5 0 5 1 5 2+
Triceps (C7) 5 2+ 5 0 5 1 5 2+
Grip (C8/T1) 5 2+ 5 0 5 1 5 2+
Iliopsoas (L2) 5 4+ 5 0 5 2 5 4+
Quadriceps (L3) 5 4+ 5 2 5 2 5 4+
Hamstrings (L4-S1) 5 4+ 5 1 5 2 5 4+
Tibialis anterior (L4) 5 4 5 0 5 2 5 4
Extensor hallucis longus (L5) 5 4 5 0 5 2 5 4
FIGURe 1 | (a) Non-contrast head CT (transverse views) shows chronic right 
anterior cerebral artery (ACA) and middle cerebral artery (MCA) territory 
encephalomalacia with sparing of a small portion of the medial right frontal 
lobe, without evidence of bleed or new territory of acute infarction. (B) Both 
transverse and midsagittal MRI views obtained during an identical clinical 
episode from 3 years prior were likewise unremarkable for acute pathology.
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paresis. Detailed review of her past medical records exposed an 
identical situation, which occurred approximately 3 years earlier, 
in the setting of a hydromorphone infusion. A full work-up at that 
time, including magnetic resonance imaging (MRI) (Figure 1B) 
and an electroencephalogram (EEG), were unrevealing, with 
symptoms having resolved approximately 24 h after discontinuing 
hydromorphone. Likewise, the presenting focal deficits witnessed 
resolved approximately 24 h after cessation of the offending agent 
(1, 2) (Table 1).
BaCKGRoUND aND DIsCUssIoN
Herein, we present the case of a woman who developed severe acute 
focal neurologic deficits in the setting of hydromorphone toxicity. 
Interestingly, the deficits gradually resolved upon cessation of the 
drug and the allowance of time for kinematic clearance, recapitulating 
an earlier documented clinical event under a similar clinical con-
text. Presently, the mechanisms behind hydromorphone-induced 
stroke recrudescence remain unknown. Early literature suggested 
a detrimental role of opioids in ischemic stroke (3–5), related to its 
ostensible hemodynamic and metabolic effects (6, 7). However, 
recent literature supports an alternative mechanism involving opioid 
receptor-mediated perturbation of neurotransmitter-specific neural 
networks critical to neuronal plasticity and recovery (8, 9). Specifically, 
following neurologic injury, a period of spontaneous recovery occurs, 
leading to the formation of new compensatory networks in perile-
sional, second-order, and homologous contralesional cortices (10, 
11). Such recovery pathways are mediated/stabilized via excitatory 
glutamate-dependent N-methyl-d-aspartate (NMDA) and α-amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, 
leading to the downstream facilitation of both neurogenesis and 
synaptogenesis (12). Interestingly, work has emerged to suggest that 
opioid-dependent Mu Receptors (MOP-R) may interfere with and 
in so doing destabilize such compensatory neuroplasticity via direct 
inhibition of presynaptic glutamate, substance P, and/or neurokinin 
release, while further disrupting postsynaptic inhibition of second-
order complexes essential for the maintenance of relatively nascent 
neural networks (13, 14).
Such MOP-R-meditated interference parallels our clinical 
observations being that the focal and highly stereotyped findings 
described within our patient cannot be explained merely by the 
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effects of general sedation alone. Therefore, our interpretation of 
the reported clinical findings is that excessive opioid exposure 
led to the functional suppression of reorganized compensatory 
cerebral networks. Of note, a similar reemergence of stroke defi-
cits has been well described following benzodiazepine (GABAA 
receptor agonist) administration (15–17). Furthermore, Thal 
et al. described a similar phenomenon in a cohort of patients with 
previously resolved neurologic deficits, who went on to develop 
the transient recurrence of prior deficits after administration of 
fentanyl (a synthetic opioid analgesic) and/or midazolam within 
months of the initial onset of their neurologic deficits (18).
It is prudent to note that an EEG was not obtained during this 
episode of recrudescence. As such, we are unable to definitively 
rule out the possibility of postictal paresis. However, the absence 
of a documented seizure history coupled with an unremarkable 
EEG during a similar clinical episode supports our assessment.
CoNCLUsIoN
This case reported herein is unique in that our patient’s prior 
motor deficits reoccurred more than 30  years after her initial 
stroke events, thereby implying that the aforementioned com-
pensatory neural networks may in fact remain susceptible well 
beyond the period of functional recovery. While preliminary, 
this case further supports the notion that opioid analgesics may 
interfere with NMDA/AMPA-receptor transmitter-specific neu-
ral networks, resulting in the recrudescence of recovered deficits, 
and should therefore be administered cautiously in patients with 
known central nervous system lesions.
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